Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tests Same-Day treatment for Cone-Shaped corneas

NCT ID NCT07629557

Disease control Sponsor: Glaukos Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether it is safe and possible to perform corneal cross-linking on both eyes on the same day in people with keratoconus, a condition where the cornea thins and bulges. Fifteen participants will receive riboflavin eye drops and UV-A light treatment in both eyes at one visit. The goal is to see if the procedure can be completed successfully without major issues.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Riboflavin eye drops and UV-A light
What this could lead to
If successful, this could allow people with keratoconus to have both eyes treated on the same day, making the procedure more convenient.
What could go wrong
This is a very small early feasibility study with only 15 participants, so results may not apply to everyone. The procedure also carries risks like infection or corneal scarring.
Why investors are watching

Glaukos is testing whether its corneal cross-linking system can safely treat both eyes of keratoconus patients on the same day, using a small 15-person study. For a small-cap company, this readout matters because it could expand the approved use of an existing product line, potentially broadening its market without a new drug or device. A positive safety and feasibility result would support a larger study or label expansion, while a negative one would stall that plan.

If it works: If the study shows same-day bilateral treatment is safe and feasible, Glaukos could pursue regulatory approval for this approach, giving doctors a reason to choose its system for more patients. That could increase sales of its cross-linking devices and goggles without needing to invent a new product.

If it fails: The trial could fail to show safety or feasibility, or the company might delay or abandon the same-day approach, which would limit the product's use to one eye at a time. Small studies like this often produce unclear results, and failure would not necessarily hurt the company's core business but would remove a potential growth path.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

13 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Provide written informed consent * Willing and able to comply with study instructions and follow-up visits * Diagnosis of keratoconus in each eye Exclusion Criteria: * Known allergy or sensitivity to study medications * History of corneal disease * Prior corneal cross-linking in either eye * Pregnant, nursing, or planning pregnancy during the study period * Participated in other investigational drug or device trial within 30 days of the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Keratoconus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

keratoconus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Keratoconus

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Glaukos Investigative Site

    RECRUITING

    Westerville, Ohio, 43082, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.